Wael Almahmeed
Overview
Explore the profile of Wael Almahmeed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
202
Citations
2850
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mezhal F, Ahmad A, Abdulle A, Leinberger-Jabari A, AlJunaibi A, Alnaeemi A, et al.
PLoS One
. 2025 Mar;
20(3):e0319648.
PMID: 40073342
Introduction: Family history of cardiovascular disease (CVD) is an independent risk factor for coronary heart disease, and the risk increases with number of family members affected. It offers insights into...
2.
Rajan R, Al Jarallah M, Daoulah A, Panduranga P, Elmahrouk A, Mohamed Al Rawahi A, et al.
J Soc Cardiovasc Angiogr Interv
. 2025 Mar;
4(1):102461.
PMID: 40061415
Background: Outcomes of patients with acute myocardial infarction-related cardiogenic shock (AMICS) stratified by the Society for Cardiovascular Angiography & Interventions (SCAI) shock stages in the Gulf region are not well...
3.
Nejabat M, Hadizadeh F, Almahmeed W, Sahebkar A
Drug Discov Today
. 2025 Feb;
30(3):104316.
PMID: 39986645
Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have potential applications in cancer therapy and as cholesterol-lowering treatments. The impact of PCSK9 suppression on both tumor growth and metastasis, as well...
4.
Abohasan A, Daoulah A, Elmahrouk A, Lotfi A, Haider O, Abozenah M, et al.
Angiology
. 2025 Feb;
:33197251319599.
PMID: 39968913
Using the SYNTAX score (SS) for decision-making between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) for left main coronary artery (LMCA) revascularization is under scrutiny. This study...
5.
Bashier A, Agrawal A, Dhanwal D, Awadi F, Awada G, Seifeldin H, et al.
Diabetes Res Clin Pract
. 2025 Feb;
221:112030.
PMID: 39909317
Aim: The Prevalence of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes across the Middle East and Africa (PACT-MEA) study compared cardiovascular disease (CVD) risk and 2021 ESC guidelines...
6.
Almahmeed W, Alabadla Z, Al Awadi F, Alrohmaihi D, AlShamiri M, Elbadawi H, et al.
Adv Ther
. 2025 Jan;
42(3):1340-1359.
PMID: 39841371
Hypertension, dyslipidemia, and type 2 diabetes are highly prevalent and poorly controlled cardiometabolic diseases in the Middle East. Therapeutic non-adherence and therapeutic inertia are major contributors to this suboptimal disease...
7.
Sabbour H, Almahmeed W, Alawadi F, Shehab A, Al Zubaidi A, Bashier A, et al.
Front Endocrinol (Lausanne)
. 2025 Jan;
15():1395630.
PMID: 39835266
Background: The combination of cardiovascular disease and diabetes is a highly prevalent condition in the United Arab Emirates. Development and dissemination of evidence-based regional recommendations for optimal screening, treatment and...
8.
Elshorbagy A, Vallejo-Vaz A, Barkas F, Lyons A, Stevens C, Dharmayat K, et al.
Eur Heart J
. 2025 Jan;
PMID: 39801189
Background And Aims: Overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and...
9.
Jamialahmadi T, Reiner Z, Simental-Mendia L, Almahmeed W, Karav S, Eid A, et al.
J Inflamm (Lond)
. 2024 Dec;
21(1):52.
PMID: 39696570
Background: Pathogenesis of atherosclerosis is largely mediated by inflammatory process. Statins are lipid-lowering drugs which also have anti-inflammatory effects. 18 fluorine radiolabeled fluorodeoxyglucose (18 F-FDG) positron emission tomography-computed tomography (PET-CT)...
10.
Jamialahmadi T, Eid A, Gadde K, Almahmeed W, Kroh M, Al Zein M, et al.
Clin Nutr
. 2024 Dec;
44():104-108.
PMID: 39647240
This opinion paper aims to discuss the influence of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on lean mass beyond its impact on weight loss. Although significant weight loss is...